Duncan Williams Asset Management LLC Purchases 301 Shares of Danaher Co. (NYSE:DHR)

Duncan Williams Asset Management LLC boosted its position in Danaher Co. (NYSE:DHR) by 7.2% in the fourth quarter, Holdings Channel.com reports. The firm owned 4,477 shares of the conglomerate’s stock after buying an additional 301 shares during the quarter. Duncan Williams Asset Management LLC’s holdings in Danaher were worth $1,028,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in DHR. Affiance Financial LLC lifted its position in Danaher by 54.4% during the 4th quarter. Affiance Financial LLC now owns 1,135 shares of the conglomerate’s stock valued at $169,000 after acquiring an additional 400 shares during the period. Patton Albertson Miller Group LLC increased its stake in shares of Danaher by 3.6% during the fourth quarter. Patton Albertson Miller Group LLC now owns 42,258 shares of the conglomerate’s stock valued at $9,700,000 after purchasing an additional 1,461 shares in the last quarter. Compass Wealth Management LLC lifted its holdings in shares of Danaher by 30.4% during the fourth quarter. Compass Wealth Management LLC now owns 33,873 shares of the conglomerate’s stock valued at $7,776,000 after purchasing an additional 7,900 shares during the last quarter. Toth Financial Advisory Corp boosted its position in shares of Danaher by 1.8% in the 4th quarter. Toth Financial Advisory Corp now owns 6,287 shares of the conglomerate’s stock worth $1,443,000 after purchasing an additional 112 shares in the last quarter. Finally, Grimes & Company Inc. increased its position in Danaher by 0.6% during the 4th quarter. Grimes & Company Inc. now owns 7,390 shares of the conglomerate’s stock valued at $1,696,000 after buying an additional 43 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Up 0.1 %

NYSE DHR opened at $245.95 on Friday. The stock’s 50-day moving average price is $235.33 and its 200-day moving average price is $253.45. The company has a market capitalization of $177.65 billion, a P/E ratio of 46.94, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. Danaher Co. has a 52 week low of $225.42 and a 52 week high of $281.70.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be issued a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.44%. The ex-dividend date of this dividend is Friday, December 27th. Danaher’s dividend payout ratio is currently 20.61%.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a report on Saturday, December 14th. Bank of America upgraded shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price target on the stock in a research note on Friday, December 13th. TD Cowen lifted their target price on shares of Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a report on Wednesday, October 23rd. Wolfe Research upgraded shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price target on the stock in a report on Thursday, October 31st. Finally, Citigroup lowered their price objective on Danaher from $305.00 to $285.00 and set a “buy” rating on the stock in a research report on Monday, January 6th. Six investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $285.55.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.